In this regard, neo-glycoconjugates (NGC) of the human milk sugar LNFPIII (LNFPIII-NGC) have therapeutic activity in vivo to treat or prevent inflammation based diseases including suppressing the severity of experimental autoimmune encephalomyelitis (EAE) and CNS inflammation[1], improving insulin sensitivity and metabolic functions in obesity[2], and prolonging allogeneic heart transplant survival[2]. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.